Tin tức & Cập nhật
Xem bài viết Gan
Xem
Chỉ hiển thị Multimedia

STRIDE regimen boosts OS in unresectable HCC
25 Feb 2022
bởiRoshini Claire Anthony
The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.
25 Feb 2022

Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?
23 Feb 2022
bởiAudrey Abella
In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.
23 Feb 2022






